Author

S. Tartare-Deckert

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 4 Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cell signaling & trafficking· 3 Research Focus:cell type annotation· 2 Assay:proteomics· 2 Research Focus:differential expression· 1

Frequent Co-Authors

A. Mallavialle· 4 shared I. Berestjuk· 3 shared M. Deckert· 3 shared M. Lecacheur· 3 shared S. Diazzi· 3 shared C. Gaggioli· 2 shared C. Girard· 2 shared C. Rovera· 2 shared

Activity by Year

2019-2021 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

4 shared papersCancer Biology

A. Mallavialle

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

The mechanosensitive TRPV2 calcium channel controls melanoma invasiveness and metastatic potential.

K. F. Shoji, E. Bayet, D. Le Devedec, A. Mallavialle, S. Marionneau-lambot, S. Leverrier-Penna, F. Rambow, R. Perret, A. Joussaume, R. Viel, A. Fautrel, A. Khammari, B. Constantin, S. Tartare-Deckert, A. Penna

This study identifies TRPV2 calcium channel as a driver of melanoma invasiveness and metastasis, showing its role in regulating cell motility and providing a therapeutic target.

bioRxiv · Oct 22, 2021Cancer Biology

Blockade of pro-fibrotic response mediated by the miR-143/-145 cluster prevents targeted therapy-induced phenotypic plasticity and resistance in melanoma

S. Diazzi, A. Baeri, J. Fassy, M. Lecacheur, O. Marin-Bejar, C. Girard, L. Lefevre, C. Lacoux, M. Irondelle, C. Mounier, M. Truchi, M. Couralet, A. Carminati, I. Berestjuk, F. Larbret, , S. Tartare-Deckert

This study identifies the miR-143/-145 cluster as a driver of therapy-resistant mesenchymal-like phenotype in melanoma and shows that blocking its pro-fibrotic effects enhances MAPK inhibitor efficacy.

bioRxiv · Jul 2, 2021Cancer Biology

Invasive dedifferentiated melanoma cells inhibit JAK1-STAT3-driven actomyosin contractility of human fibroblastic reticular cells of the lymph node

C. Rovera, I. Berestjuk, M. Lecacheur, S. Diazzi, A. Mallavialle, J. Albrengues, C. Gaggioli, C. C. Girard, T. Passeron, M. Deckert, S. Tartare-Deckert, V. Prod'homme

The paper shows that dedifferentiated melanoma cells inhibit FRC contractility via JAK1-STAT3 and YAP pathways, reducing actomyosin forces and promoting LN remodeling.

bioRxiv · Mar 25, 2021 · PreprintCancer Biology

A 9-kDa matricellular SPARC fragment released by cathepsin D exhibits pro-tumor activity in the triple-negative breast cancer microenvironment

L. B. Alcaraz, A. Mallavialle, T. David, D. Derocq, F. Delolme, C. Dieryckx, F. Boissiere-Michot, J. Simony-Lafontaine, S. Du Manoir, P. Huesgen, C. M. Overall, S. Tartare-Deckert, W. Jacot, T. Chardes, S. Guiu, , E. Liaudet-Coopman

The paper identifies a 9-kDa SPARC fragment released by cathepsin D in TNBC that promotes tumor progression by enhancing cell migration and invasion.

bioRxiv · Oct 22, 2020 · PreprintCancer Biology

Targeting DDR1 and DDR2 overcomes matrix-mediated melanoma cell adaptation to BRAF-targeted therapy

S. Tartare-Deckert, I. Berestjuk, M. Lecacheur, S. Diazzi, C. Rovera, V. Prod'homme, A. Mallavialle, F. Larbret, S. Pisano, S. Audebert, T. Passeron, C. Gaggioli, C. Girard, M. Deckert

This study shows that targeting DDR1 and DDR2 overcomes matrix-mediated resistance to BRAF inhibitors in melanoma by disrupting ECM-driven survival pathways.

bioRxiv · Nov 28, 2019 · PreprintCancer Biology